Aligos Therapeutics Q4 2023 Earnings Report

Aligos Therapeutics EPS Results

• Actual EPS: -$5.50
• Consensus EPS: -$6.75
• Beat/Miss: Beat by +$1.25
• One Year Ago EPS: N/A

Aligos Therapeutics Revenue Results

• Actual Revenue: $2.68 million
• Expected Revenue: $3.20 million
• Beat/Miss: Missed by -$520.00 thousand
• YoY Revenue Growth: N/A

Aligos Therapeutics Announcement Details

• Quarter: Q4 2023
• Date: 3/12/2024
• Time: N/A

Aligos Therapeutics (NASDAQ:ALGS), a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.